Physician profile
Karin Hickey
NPI 1649591645
$2,112.44
in general payments reported to CMS, 2019-2025
20 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.97 · 2021: $88.47 · 2022: $487 · 2023: $632 · 2024: $468 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.72 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $459.34 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $456.58 | 2019-2024 | Prolia, Evenity |
| Beta Bionics, INC. | $158.15 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $145.60 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $128.18 | 2022-2025 | Omnipod |
| Dexcom, INC. | $90.86 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $89.11 | 2021-2025 | Minimed 780g |
| Ucb, INC. | $84.61 | 2022 | |
| Radius Health, INC. | $74.59 | 2021-2024 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $74.57 | 2023-2024 | Baqsimi |
| Mannkind Corporation | $59.59 | 2025 | |
| Abbott Laboratories | $54.09 | 2022-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $48.26 | 2022 | |
| Alvogen INC | $44.15 | 2023 | Teriparatide |
| Novo Nordisk INC | $39.38 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $30.67 | 2022 | |
| Ascendis Pharma Endocrinology INC | $23.75 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $20.50 | 2024 | |
| Sequel Med Tech, LLC | $17.39 | 2025 | Twiist |
| Acella Pharmaceuticals, LLC | $13.07 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Hickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.